Treprostinil palmitil is a Small Molecule owned by Insmed, and is involved in 6 clinical trials, of which 1 was completed, 3 are ongoing, and 2 are planned.

Treprostinil palmitil is a prostacyclin receptor agonist. Prostacyclin receptor is the G-protein coupled receptor (GPCR) that upon binding of prostacyclin gets activated to cause inhibition of platelet aggregation, relaxation and vasodilatation of the pulmonary arteries, thereby checking the disease progression.

The revenue for Treprostinil palmitil is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Treprostinil palmitil NPV Report.

Treprostinil palmitil is currently owned by Insmed.

Treprostinil palmitil Overview

Treprostinil palmitil is under development for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug candidate is a sustained release prodrug nanoparticle formulation. It is administered as dry powder inhalation. The drug candidate acts by targeting prostacyclin receptor. 

It was also under development for the treatment of idiopathic pulmonary fibrosis.

Insmed Overview

Insmed is a biopharmaceutical company that focuses on developing novel therapeutics for rare diseases. Its marketed product, Arikayce (liposomal amikacin for inhalation) is indicated for mycobacterium avium complex (MAC) lung infection and NTM lung infections caused by MAC in adult patients. The company uses its proprietary, liposomal technology to develop its novel drug candidates. Its pipeline products include brensocatib for non-cystic fibrosis (non-CF) bronchiectasis, cystic fibrosis and COVID-19; TPIP, an inhaled formulation of a treprostinil prodrug for pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis, and PAH associated with interstitial lung diseases. The company operates in the US, the UK, the Netherlands, Ireland, Italy, Germany, France and Japan through its subsidiaries. Insmed is headquartered in Bridgewater, New Jersey, the US.

The company reported revenues of (US Dollars) US$188.5 million for the fiscal year ended December 2021 (FY2021), an increase of 14.6% over FY2020. The operating loss of the company was US$392.8 million in FY2021, compared to an operating loss of US$265.2 million in FY2020. The net loss of the company was US$434.7 million in FY2021, compared to a net loss of US$294.1 million in FY2020. The company reported revenues of US$67.7 million for the third quarter ended September 2022, an increase of 3.8% over the previous quarter.

Quick View – Treprostinil palmitil

Report Segments
  • Innovator
Drug Name
  • Treprostinil palmitil
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Cardiovascular
  • Respiratory
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.